直到最后：在过继细胞治疗期间跟踪 T 细胞克隆型动态。
TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapy.
发表日期：2024 Oct 08
作者：
Anthony C Buzzai, Thomas Tüting
来源：
IMMUNITY
摘要：
了解导致使用肿瘤浸润淋巴细胞（TIL-ACT）的过继性细胞疗法取得成功的因素将改善当前的治疗方案。在本期《免疫》中，Chiffelle 等人。全面比较 ACT 过程中有反应和无反应患者的 CD8 T 细胞克隆型动态。版权所有 © 2024 Elsevier Inc. 保留所有权利。
Understanding the factors that lead to the therapeutic success of adoptive cell therapies using tumor-infiltrating lymphocytes (TIL-ACT) will improve current treatment protocols. In this issue of Immunity, Chiffelle et al. comprehensively compare the dynamics of CD8+ T cell clonotypes during the course of ACT between responding and non-responding patients.Copyright © 2024 Elsevier Inc. All rights reserved.